carlumab

{
  "id": "MLC-T-ONC-012310",
  "term": "carlumab",
  "field": "Oncology and biomedicine",
  "definition": "A human IgG1 kappa monoclonal antibody directed against human CC chemokine ligand 2 (CCL2) with potential antineoplastic activity. Carlumab binds to and inhibits CLL2, which may result in inhibition of angiogenesis and, so, tumor cell proliferation. Endothelium-derived CLL2 (monocyte chemoattractant protein; MCP1) is a member of the beta-chemokine family, can stimulate monocyte/macrophage migration and smooth muscle cell (SMC) proliferation, and plays a role in angiogenesis and tumor cell migration; CCL2 induction of angiogenesis may involve the upregulation of hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression which, in turn, induces vascular endothelial growth factor-A (VEGF-A) gene expression.",
  "synonyms": [
    "anti-CCL2 human monoclonal antibody CNTO 888",
    "anti-human small-inducible cytokine A2 monoclonal antibody CNTO 888",
    "immunoglobulin G1, anti-(human monocyte chemoattractant protein-1) (human monoclonal CNTO888 gamma 1-chain), disulfide with human monoclonal CNTO888 kappa-chain, dimer"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/carlumab/"
}